Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
about
Immune checkpoint blockade for hematologic malignancies: a reviewPembrolizumab in cervical cancer: latest evidence and clinical usefulness.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Hereditary pancreatic cancer: related syndromes and clinical perspective.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.Atezolizumab for the treatment of non-small cell lung cancer.Cardiovascular Complications Associated With Novel Cancer Immunotherapies.BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Targeted Therapies for Melanoma Brain Metastases.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.Advancing Immune and Cell-Based Therapies Through Imaging.Recent progress in immunotherapy for urological cancer.The immune contexture in cancer prognosis and treatment.Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma PatientsTranslational significance of multi-dimensional omicsUnderstanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.The tissue distribution and significance of B7-H4 in laryngeal carcinoma.EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: A case report and review of the literatures.Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.Informatics for cancer immunotherapy.Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.Trial watch: Immune checkpoint blockers for cancer therapy.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.Discovery and application of immune biomarkers for hematological malignancies.Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study.
P2860
Q33645590-A1EF12C3-6312-43AA-8E4F-909CC6B77DD4Q33757149-48AB1902-CA6F-4969-8DD6-89F21CCF1A9BQ33839204-A2512EE2-FEB2-4E73-B452-2842D9B5117BQ33851085-D4D17A48-799F-46C4-8A24-DD1A19BC68DBQ36358014-7890E11F-BD10-4621-9ECF-38A0850BA930Q37729169-3E713B7A-0F48-4B74-908C-7A068C21DC2BQ38374885-2F03D81C-3FB2-45F4-981B-A0266284A412Q38642853-08B4305E-DD0D-48E4-A26D-776EAFB00A46Q38645338-D8C558BF-F1CB-4899-81F5-497C7601E333Q38675969-3B8CA0AC-260E-4741-AF1C-728F316FC6FFQ38731522-7AEBC14B-0580-43BD-B018-464F508B2EEFQ38744477-1427FAE2-5178-493A-AE4B-E852EA9461B0Q38819982-CAD43BAF-EE3C-4827-8DB4-6B331A363682Q38857040-2319C60C-3243-44B2-BAE8-8FF0BD48FA9AQ38920328-4EE03B1B-19EF-49E5-9E2F-16C126857BFFQ39167485-A4FA4490-0986-403B-B998-C7B0DCD4F26FQ39388043-F7AF4442-93BE-4C0C-BAB4-FE3217855EE7Q39456999-1A067D34-74AD-45EC-9F58-C9BBD338101EQ40185369-67E4CDC7-66B6-473E-8713-29995629629FQ40496586-554CCCC5-C41E-4290-9AB9-3025BE6AC072Q41173680-8DE387B8-B339-483D-9B37-C56A0EF4C74EQ41693862-53CD7116-527D-40DF-9CA0-F7C46DB2F298Q42322231-C9EAEDD4-F96A-4029-9D7A-D24E19190D94Q42376660-6B0B2288-D467-4106-B589-F6F8B76C1241Q45242086-60398C85-5389-46AF-9D79-98E05B8E6407Q46037449-58C9DB84-B2F4-4E30-A4C6-131889E29572Q47101155-A0821647-0AAE-415A-8711-A17E29CF9665Q47102186-9FE6E04B-D948-4E8E-8C55-24F53150CA9EQ47102275-62B77040-C46C-4BF6-A8A4-84F4740EA12FQ47104481-8A17F1B8-CA4E-4909-AFD6-753AD825452CQ47130162-2A83C857-3B6B-4818-9D92-E13C2DCE46D0Q47166342-AFF86D8A-F715-4ADF-950A-A86A520AFE90Q47273046-20F19B41-3769-48B8-BDA5-12E2DC1602A2Q47290509-804433DC-68AF-4049-B729-82BD7652BA73Q47323319-88F873EF-82F0-490E-AB30-98A08D000EEAQ47393365-E6ACF45D-C507-4D53-8018-1FD4F8E817F5Q47394131-12DCD80E-DBD5-49C1-AC25-C6826251EF7DQ47621538-F34F989C-7EAA-40BC-9AA2-A78C5B0B6A4EQ47681393-3FF41B74-B099-4169-90C6-77EA89333E19Q47718948-02DF8A66-B20B-47AF-BB49-DCB6BE39A4C3
P2860
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
@en
type
label
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
@en
prefLabel
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
@en
P2093
P2860
P1433
P1476
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
@en
P2093
Geoffrey T Gibney
Louis M Weiner
Michael B Atkins
P2860
P304
P356
10.1016/S1470-2045(16)30406-5
P577
2016-12-01T00:00:00Z